Lipocine Inc. Files 8-K: Other Events & Financials
Ticker: LPCN · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financials
TL;DR
Lipocine filed an 8-K today for other events and financials.
AI Summary
Lipocine Inc. filed an 8-K on December 17, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific transactions or financial results but serves as a notification of these items being filed.
Why It Matters
This 8-K filing indicates that Lipocine Inc. has submitted important updates regarding its business operations and financial status to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of events and financial statements without immediate material impact disclosed.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- December 17, 2024 (date) — Date of Earliest Event Reported
- 801-994-7383 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K?
The provided text of the 8-K filing indicates 'Other Events' as an item information, but does not specify the nature of these events.
When was this 8-K filing submitted to the SEC?
The filing was submitted on December 17, 2024.
What is the Commission File Number for Lipocine Inc.'s 8-K filing?
The Commission File Number is 001-36357.
Where is Lipocine Inc. headquartered?
Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
Does this filing provide details on Lipocine Inc.'s financial performance?
The filing lists 'Financial Statements and Exhibits' as an item information, suggesting financial information is included, but the specific details are not provided in the excerpt.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-12-17 09:30:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 23KB
- form8-k_001.jpg (GRAPHIC) — 24KB
- 0001493152-24-050346.txt ( ) — 298KB
- lpcn-20241217.xsd (EX-101.SCH) — 3KB
- lpcn-20241217_lab.xml (EX-101.LAB) — 33KB
- lpcn-20241217_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: December 17, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer